Since up to 50% of all MS patients do not benefit from IFN-β treatment or respond only partially, genetic biomarkers that are predictive of the patient’s response to IFN-β therapy are of major importance, and are the focus of many studies [17]–[19]. This evidence concerns the gene IFNB1 and myeloid sarcoma.